Abstract
Abstract
While the acute sensation of pain is protective, signaling the presence of actual or potential bodily harm, its persistence is unpleasant. When pain becomes chronic, it has limited evolutionarily advantage. Despite the differing nature of acute and chronic pain, a common theme is that sufferers seek pain relief. The possibility to medicate pain types as varied as a toothache or postsurgical pain reflects the diverse range of mechanism(s) by which pain-relieving “analgesic” therapies may reduce, eliminate, or prevent pain. Systemic application of an analgesic able to cross the blood–brain barrier can result in pain modulation via interaction with targets at different sites in the central nervous system. A so-called supraspinal mechanism of action indicates manipulation of a brain-defined circuitry. Pre-clinical studies demonstrate that, according to the brain circuitry targeted, varying therapeutic pain-relieving effects may be observed that relate to an impact on, for example, sensory and/or affective qualities of pain. In many cases, this translates to the clinic. Regardless of the brain circuitry manipulated, modulation of brain processing often directly impacts multiple aspects of nociceptive transmission, including spinal neuronal signaling. Consideration of supraspinal mechanisms of analgesia and ensuing pain relief must take into account nonbrain-mediated effects; therefore, in this review, the supraspinally mediated analgesic actions of opioidergic, anti-convulsant, and anti-depressant drugs are discussed. The persistence of poor treatment outcomes and/or side effect profiles of currently used analgesics highlight the need for the development of novel therapeutics or more precise use of available agents. Fully uncovering the complex biology of nociception, as well as currently used analgesic mechanism(s) and site(s) of action, will expedite this process.
Publisher
Springer Science and Business Media LLC
Subject
Pharmacology (medical),Clinical Neurology,Pharmacology
Reference59 articles.
1. Basbaum, A.I. and H.L. Fields, Endogenous pain control systems: brainstem spinal pathways and endorphin circuitry. Annu Rev Neurosci, 1984. 7: p. 309-38.
2. Xu, M., Petraschka, M., McLaughlin, JP. et al., Neuropathic pain activates the endogenous kappa opioid system in mouse spinal cord and induces opioid receptor tolerance. J Neurosci, 2004. 24(19): p. 4576-84.
3. Gutstein, H.B., Mansour, A., Watson, SJ. et al., Mu and kappa opioid receptors in periaqueductal gray and rostral ventromedial medulla. Neuroreport, 1998. 9(8): p. 1777-81.
4. Yaksh, T.L., J.C. Yeung, and T.A. Rudy, Systematic examination in the rat of brain sites sensitive to the direct application of morphine: observation of differential effects within the periaqueductal gray. Brain Res, 1976. 114(1): p. 83-103.
5. Dickenson, A.H., J.L. Oliveras, and J.M. Besson, [Role of the Raphe Magnus nucleus in morphine analgesia : studies with intracerebral microinjections in the rat]. C R Acad Hebd Seances Acad Sci D, 1978. 287(10): p. 955-8.
Cited by
21 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献